|
Phase IV, single-blind, randomised, multicenter study to evaluate immediate post-vaccination pain, reactogenicity and tolerance of GSK Bio’s Measles-Mumps-Rubella vaccine (Priorix) administered as a second dose compared to Aventis-Pasteur-MSDs Measles-Mumps-Rubella vaccine (ROR Vax) |
Measles, Mumps, Rubella Vaccine |
209762/149 (MeMuRu-149) |
|
Measles; Mumps; Rubella |
Phase 4 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
June 2015 |